<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04851444</url>
  </required_header>
  <id_info>
    <org_study_id>SI-F019-101</org_study_id>
    <nct_id>NCT04851444</nct_id>
  </id_info>
  <brief_title>A Study of SI-F019 in Healthy Participants</brief_title>
  <official_title>A Phase I Clinical Study on the Safety, Tolerability and Pharmacokinetics of SI-F019 Recombinant Human Bivalent ACE2-Fc Fusion Protein Injection in a Single Dose in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sichuan Baili Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>SystImmune Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Sichuan Baili Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety, tolerability and pharmacokinetic properties of a single intravenous&#xD;
      administration of SI-F019 recombinant human bivalent ACE2-Fc fusion protein injection in&#xD;
      healthy participants, and provide a basis for the design of subsequent clinical trials.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 30, 2021</start_date>
  <completion_date type="Anticipated">September 20, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 20, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>SAE</measure>
    <time_frame>Up to 29 days after the first dose of SI-F019</time_frame>
    <description>Number of Adverse Events and Seriuos Adverse Events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>7 days</time_frame>
    <description>Maximum Time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2</measure>
    <time_frame>7 days</time_frame>
    <description>half time</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>SI-F019</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SI-F019 administered intravenously (IV).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SI-F019</intervention_name>
    <description>Single dose is administered IV.</description>
    <arm_group_label>SI-F019</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. The participants fully understand the purpose, character, methods and possible adverse&#xD;
             events of the trial, and volunteer to be the subject, and sign the informed consent&#xD;
             form before the start of any study procedure, and guarantee that any procedure will be&#xD;
             participated in the study by the participants themselves;&#xD;
&#xD;
          2. The participant could communicate well with the investigator, and understand and&#xD;
             comply with the requirements of this study.&#xD;
&#xD;
          3. The participant has no history of chronic diseases or serious diseases such as&#xD;
             cardiovascular, liver, kidney, breathing, blood and lymph, endocrine, immune, mental,&#xD;
             nervous, gastrointestinal system, and is in good general health;&#xD;
&#xD;
          4. The participants (including male subjects) have no pregnancy plan and voluntarily take&#xD;
             effective contraceptive measures during the screening period and within the next 6&#xD;
             months, and no sperm or egg donation plan, in which non-drug contraceptive measures&#xD;
             should be used voluntarily during the trial period;&#xD;
&#xD;
          5. Male or female subjects aged 18 to 45 (including 18 and 45 years old);&#xD;
&#xD;
          6. Male weight ≥50.0 kg, female weight ≥45.0 kg; body mass index (BMI) is in the range of&#xD;
             19.0~26.0 kg/m2 (including cut-off value);&#xD;
&#xD;
          7. Vital signs examination, physical examination, clinical laboratory examination (blood&#xD;
             routine, urine routine, blood biochemistry, blood transfusion, blood coagulation&#xD;
             function, pregnancy test (female), alcohol and drug screening, etc.), 12-lead&#xD;
             electrocardiogram and Abdominal B-ultrasound examination showed no abnormalities or&#xD;
             abnormalities without clinical significance.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Health condition: clinically significant medical history of heart, liver, kidney,&#xD;
             digestive tract, nervous system, respiratory system, blood and lymph system, immune&#xD;
             system, mental and metabolic abnormalities, and bones;&#xD;
&#xD;
          2. Those who have a history of allergies to biological agents or any drug component;&#xD;
             those who have a history of allergies and are judged not to be included in the group&#xD;
             by the investigator;&#xD;
&#xD;
          3. Those who have undergone surgery within 3 months before screening, or who plan to&#xD;
             undergo surgery during the study period, and those who have undergone surgery that&#xD;
             will affect drug absorption, distribution, metabolism, and excretion;&#xD;
&#xD;
          4. Those who cannot tolerate venipuncture or have a history of fainting needles and&#xD;
             bleeding;&#xD;
&#xD;
          5. Those who have a history of drug abuse within 6 months before screening;&#xD;
&#xD;
          6. Used drugs within 3 months before screening;&#xD;
&#xD;
          7. Those who donated blood including blood components or a large amount of blood loss&#xD;
             (≥200mL) within 3 months before screening, received blood transfusion or used blood&#xD;
             products;&#xD;
&#xD;
          8. The participant (female) is in pregnancy or lactation during the screening period or&#xD;
             the test process;&#xD;
&#xD;
          9. The participant has a birth plan or sperm donation or egg donation plan during the&#xD;
             screening period and the next 6 months;&#xD;
&#xD;
         10. Those who have used any prescription drugs, over-the-counter drugs, and Chinese herbal&#xD;
             medicines within 2 weeks before screening;&#xD;
&#xD;
         11. Those who have received vaccination within 4 weeks before screening, or plan to&#xD;
             receive vaccination during the study period;&#xD;
&#xD;
         12. Those who smoked more than 5 cigarettes per day in the 3 months before screening, or&#xD;
             who could not stop using any tobacco products during the trial period;&#xD;
&#xD;
         13. Drinking more than 14 units per week in the 3 months before screening (1 unit of&#xD;
             alcohol ≈ 360 mL of beer or 45 mL of spirits with 40% alcohol content or 150 mL of&#xD;
             wine), or those who cannot abstain from alcohol during the test;&#xD;
&#xD;
         14. Those who have special requirements for diet and cannot accept a unified diet;&#xD;
&#xD;
         15. Those who have participated in drug clinical trials and used trial drugs within 3&#xD;
             months before screening;&#xD;
&#xD;
         16. Received immunosuppressive agents or monoclonal antibodies before screening;&#xD;
&#xD;
         17. For patients with abnormal vital signs that have clinical significance, refer to the&#xD;
             normal range (including cut-off values): sitting systolic blood pressure 90~139mmHg,&#xD;
             diastolic blood pressure 60~89mmHg, pulse 60-100 beats/min, body temperature (ear&#xD;
             temperature) 35.4~37.7℃, breathing 16-20 times/min, the specific situation will be&#xD;
             judged comprehensively by the investigator;&#xD;
&#xD;
         18. Any abnormality in laboratory examinations and auxiliary examinations, and the&#xD;
             investigator judges that it has clinical significance;&#xD;
&#xD;
         19. One or more of hepatitis B virological indicators, hepatitis C virus antibody,&#xD;
             anti-human immunodeficiency virus antibody or anti-Treponema pallidum specific&#xD;
             antibody test has one or more clinical significance;&#xD;
&#xD;
         20. Female participants who have a positive urine or blood pregnancy test result during&#xD;
             the screening period;&#xD;
&#xD;
         21. Alcohol breath test results greater than 0.0mg/100mL or drug screening positive&#xD;
             (morphine, methamphetamine, ketamine, ecstasy (dimethyldioxyamphetamine), cannabis&#xD;
             (tetrahydrocannabinolic acid);&#xD;
&#xD;
         22. Acute illness occurred during the period from screening to -1 day of admission;&#xD;
&#xD;
         23. Those who have taken any prescription drugs, over-the-counter drugs, or Chinese herbal&#xD;
             medicines during the period from screening to -1 day of admission;&#xD;
&#xD;
         24. The investigator determines that the participant is not suitable for the trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hongzhou Lu</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai Public Health Clinical Center Ethics Committee Approval Letter</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hai Zhu</last_name>
    <phone>+86-13980051002</phone>
    <email>zhuhai@baili-pharm.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sa Xiao</last_name>
    <phone>+86-15013238943</phone>
    <email>xiaosa@baili-pharm.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Shanghai Public Health Clinical Center Ethics Committee Approval Letter</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>201508</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hongzhou Lu</last_name>
      <phone>+86-18930810088</phone>
    </contact>
    <contact_backup>
      <last_name>Xianming Meng</last_name>
      <phone>+86-18916081980</phone>
    </contact_backup>
    <investigator>
      <last_name>Hongzhou Lu</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Xianming Meng</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>April 12, 2021</study_first_submitted>
  <study_first_submitted_qc>April 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 20, 2021</study_first_posted>
  <last_update_submitted>August 22, 2021</last_update_submitted>
  <last_update_submitted_qc>August 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

